# A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

> **NCT06551324** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 600 (estimated)

## Conditions studied

- Metastatic Castrate Resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** PF-06821497
- **DRUG:** Docetaxel
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT06551324
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-21
- **Primary completion:** 2026-07-13
- **Final completion:** 2028-10-29
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06551324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06551324, "A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06551324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*